![Philip Dawson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Philip E.
Dawson is the founder and currently holds the position of Director at Elsie Biotechnologies Inc., which is founded in 2021.
Cargos activos de Philip Dawson
Empresas | Cargo | Inicio |
---|---|---|
Elsie Biotechnologies Inc.
![]() Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Fundador | 01/01/2021 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Elsie Biotechnologies Inc.
![]() Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Health Technology |
- Bolsa de valores
- Insiders
- Philip Dawson